

Press Release

Astellas Announces Acquisition of Own Shares and Cancellation of Treasury Stock

- *Acquisition of own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act and cancellation of treasury stock pursuant to the provisions of Article 178 of the Companies Act -*

TOKYO, February 2, 2022 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its own shares pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act. The Company also announced that it decided to cancel its treasury stock pursuant to the provisions of Article 178 of the Companies Act. The details are as follows.

1. Reasons for the acquisition of own shares

To improve capital efficiency and shareholder return.

2. Details of the acquisition of own shares

(1) Class of shares to be acquired: Common stock of the Company

(2) Total number of shares to be acquired: Up to 29 million shares

(Ratio to the total number of shares outstanding [excluding treasury stock]: 1.57%)

(3) Total amount of acquisition cost: Up to 50 billion yen

(4) Period of acquisition: From February 3, 2022 to March 24, 2022

3. Details of the cancellation of treasury stock

(1) Class of shares to be cancelled: Common stock of the Company

(2) Number of shares to be cancelled: All of the shares acquired as stated in 2 above

(3) Cancellation date: March 29, 2022 (planned)

- * The actual number of shares to be cancelled will be announced after completing the acquisition of own shares stated in 2 above.

(Reference) Status of treasury stock as of December 31, 2021:

Total number of shares outstanding (excluding treasury stock): 1,852,927,335 shares

Total number of treasury stocks: 8,859,740 shares

About Astellas

Astellas Pharma Inc. is a pharmaceutical company conducting business in more than 70 countries around the world. We are promoting the Focus Area Approach that is designed to identify opportunities for the continuous creation of new drugs to address diseases with high unmet medical needs by focusing on Biology and Modality. Furthermore, we are also looking beyond our foundational Rx focus to create Rx+[®] healthcare solutions that combine our expertise and knowledge with cutting-edge technology in different fields of external partners. Through these efforts, Astellas stands on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at <https://www.astellas.com/en>.

Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

###

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Advocacy & Relations
TEL: +81-3-3244-3201